Alexion CEO and CFO Depart
13 December 2016 - 1:00AM
Dow Jones News
Alexion Pharmaceuticals Inc. outlined a shake-up of its top
ranks on Monday, saying its chief executive and finance chief have
left the company, effective immediately.
Connecticut-based Alexion said CEO David Hallal is resigning for
personal reasons after 20 months in the position, to be replaced on
an interim basis by board member and former AstraZeneca PLC CEO
David Brennan. The company will launch a search for a permanent
CEO.
CFO Vikas Sinah, meanwhile, will be succeeded by David Anderson,
who left Honeywell International Inc. in 2014 after 11 years as
CFO. Mr. Sinah, who spent 11 years at Alexion, is leaving to pursue
other opportunities, the company said. In September, Mr. Vikas
joined the board of drug-development firm Verona Pharma PLC.
Alexion is in the midst of an internal audit investigation
related to a former employee's allegation of deceptive sales
practices. The company said its committee hasn't found any facts
that require the company to revise its financial results.
Write to Imani Moise at imani.moise@wsj.com
(END) Dow Jones Newswires
December 12, 2016 08:45 ET (13:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024